Primary Hepatic Lymphoma: A Complex and Challenging Diagnosis

Rinku Joshi1, Pritanjali Singh2, Dhan Bahadur Shrestha3

1Department of Medicine, 3 Medical Student; Nepalese Army Institute of Health Sciences, Shree Birendra Hospital, Kathmandu, Nepal; 2Department of Radiotherapy, All India Institute of Health Sciences, Patna, India.

INTRODUCTION

Primary hepatic lymphoma (PHL) is an uncommon subset of extranodal lymphoma that accounts for < 1% of all extranodal lymphomas.1,2 Misdiagnosis and mistreatment is very frequent because of its rarity, non-specific clinical symptoms, laboratory and radiological resemblance to other space occupying liver lesions like focal nodular hyperplasia, primary hepatocellular carcinoma (HCC), carcinoma with hepatic metastases, and systemic lymphoma with secondary hepatic involvement.3-5

Here we present a case of an immunocompetent young male patient with primary diffuse large B-cells non-Hodgkin lymphoma (NHL) presenting as dull pain and swelling right upper abdomen accompanied by prodromal symptoms.

CASE REPORT

A 20-year-old student with no significant prior medical and family history presented to our hospital with 2-month history of dragging pain in the right upper quadrant, relieved with analgesics. Abdominal pain was accompanied by swelling over the same region, fever, loss of appetite, and night sweats. He did not mention having vomiting, diarrhea, blood in stools, jaundice or weight loss.

On clinical examination, there was mild pallor, a temperature of 38.5 °C (101.3 °F), pulse rate of 96 beats per minutes and blood pressure of 100/70 mm Hg. There was non-tender hepatomegaly with the liver span of 16 cm. However, there were no signs of liver disease including jaundice, ascites and splenomegaly. No peripheral lymphadenopathy was appreciated. Scrotal examination was normal. Other systemic findings were unremarkable.

Laboratory tests revealed a normocytic anemia with hemoglobin level of 10.6 gm% and a normal WBC count with a normal differentiation. Renal function test with electrolytes, liver-function tests, carcinoembryonic antigen (CEA), CA 19-9, and α-
fetoprotein were all normal. Serology was negative for HIV, Hepatitis C and B virus. Serum calcium level was not elevated. However, lactate dehydrogenase (LDH) was markedly raised (2379 U/L).

Radiology of chest did not reveal any mediastinal lymphadenopathy. Abdominal ultrasound depicted multiple hypoechoic lesions with internal echogenic septation in both lobes of liver with exophytic component in gastro-hepatic region. Abdominal computed tomography (CT) scan showed well defined, homogenous, hypodense, minimally/non-enhanced space occupying lesions with geographical lobulated borders, one each in right lobe, left lobe & caudate lobe of liver, largest about 15 X 12 cm in right lobe. (Figure 1)

The possibility of malignant mass of liver was made at this stage. Ultrasound (USG) guided fine needle aspiration cytology (FNAC) was done which revealed findings consistent with NHL. He further underwent USG guided trucut biopsy from the right liver lobe nodule which showed diffuse infiltrates of small to intermediate atypical sized round cells with oval to indented nuclei, dark smudged chromatin and inconspicuous nucleoli with scanty cytoplasm, admixed with few small lymphocytes and eosinophils (Figure 2(a)).

Immunohistochemical (IHC) staining demonstrated CD20 positive cells and confirmed the presence of cells of the B-lymphocyte lineage (Figure 2(b)).

Considering the rarity of PHL, bone marrow biopsy was advised which showed normal cellularity with trilineage haematopoiesis in normal proportion. CT-scan chest showed no other foci of lymphoma in the body.

Considering liver to be the only site of lymphoma, he received the diagnosis of PHL, Stage IVEBX. He was promptly started on 6 cycles of R-CHOP regimen based on his BSA. On subsequent follow up, improvements were markedly observed in terms of clinical, laboratory and radiological parameters. (Figure 3)

DISCUSSION

Extranodal lymphomas are responsible for 10% to 25% of NHL. Of all primary extranodal NHL only 0.4% arises in the liver. The incidence of hepatic involvement in NHL is described between 16% and 22%. The etiology of this disease may have an association with viral infections, liver cirrhosis, primary biliary cirrhosis, immunosuppressive therapy and autoimmune disease. However, our patient had none of these.

PHL typically occurs in middle-aged men (median age, 50 to 55 years), with the most common presentation being pain in the right upper quadrant, fever, weight loss, and night sweats as were present in our patient. Prodromal symptoms may accompany these symptoms. A physical examination commonly reveals hepatomegaly (in approximately 80% of cases) and, less frequently, jaundice, splenomegaly, ascites, or pleural effusions. An incidental diagnosis without preceding symptoms has been reported in 10% of patients. Diffuse and infiltrative histologic patterns have been reported, with diffuse one being predominant, as was true for our patient. Other types (<5 %) are immunoblastic, lymphoblastic, Burkitt’s lymphomas, mucosa-associated lymphoid tissue lymphomas, anaplastic large-cell lymphoma, and rarely T cell type.
Laboratory findings usually include abnormal liver enzymes, lactate dehydrogenase, and β-microglobulin, with an almost invariably normal α-fetoprotein and carcinoembryonic antigen. Hypercalcemia is observed in 40% of patients possibly due to release of calcitriol by malignant lymphoma cells. Ultrasound is a simple, noninvasive and good screening test, which classically shows hypo-echoic lesions. The abdominal CT scan shows hypo-attenuating masses, unenhanced or poorly enhanced after contrast. The findings with magnetic resonance imaging may shows hypo-intense lesions on T₁-weighted and hyper-intense in T₂-weighted. Liver biopsy remains the most valuable tool for diagnosis of PHL (percutaneous / transjugular). Immunohistochemical typing is needed to differentiate lymphoma from other malignancies.

Surgery, chemotherapy, and radiotherapy are treatment options of PHL. R-CHOP is used for CD20⁺ tumors. Surgery is indicated for localized disease and surgical debulking before or after chemotherapy. Adjuvant chemotherapy after complete surgical resection results in complete remission of disease.

Poor prognostic features include advanced age, constitutional symptoms, bulky disease, unfavorable histologic subtype, elevated levels of LDH and β2-microglobulin, a high proliferation rate, cirrhosis, and comorbid conditions. The appreciation of prognostic factors in our patient enabled us to predict a moderately good prognosis.

CONCLUSIONS

PHL is a rare entity that should be considered as differential diagnosis of space occupying liver lesions with normal levels of alpha-fetoprotein and CEA. The rarity of the disease leads to problems of diagnosis and management. If the clinical picture and imaging findings on CT scans and MRI are nonspecific, a liver biopsy is needed not only for a definitive diagnosis but also for identifying the immunophenotype of the lesion.

It is important to recognize PHL because it is chemosensitive and may have a better prognosis than hepatocellular carcinoma or metastatic disease of the liver. Surgery may be proposed in the nodular forms, with adjuvant chemotherapy; which is highly recommended to reduce the rate of extra-hepatic recurrence.

REFERENCES
